Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 7/20 | 0.39 |
| ▸ | KLK7 | P49862 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16376172 | 0.90 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1EPHX1NAAA | |
| SCHEMBL16380566 | 0.89 | SMN1; SMN2 (0.44) | SMN1; SMN2MEN1MAPTKMT2AATM | |
| SCHEMBL29089247 | 0.81 | NAAA (0.53) | SMN1; SMN2MEN1MAPTKMT2AATM | |
| SCHEMBL8084714 | 0.80 | EPHX2 (0.54) | SMN1; SMN2MEN1MAPTKMT2AATM | |
| SCHEMBL16380567 | 0.79 | SMN1; SMN2 (0.49) | SMN1; SMN2MAPTALDH1A1EPHX1NAAA | |
| SCHEMBL31323803 | 0.78 | EPHX1 (0.48) | SMN1; SMN2MEN1MAPTKMT2AATM | |
| SCHEMBL16376169 | 0.77 | ADRB2 (0.38) | MEN1KMT2AALDH1A1NAAA | |
| SCHEMBL29549527 | 0.77 | HTR2C (0.36) | NAAA | |
| SCHEMBL8413450 | 0.76 | MEN1 (0.52) | SMN1; SMN2MEN1MAPTKMT2AATM | |
| SCHEMBL16376163 | 0.75 | ALDH1A1 (0.39) | MEN1KMT2AALDH1A1NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9463247-B2 | Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-20150005363-A1 | Branched Alkyl And Cycloalkyl Terminated Biodegradable Lipids For The Delivery Of Active Agents | BANK OF AMERICA, N.A. | 2015-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005363-A1 | Branched Alkyl And Cycloalkyl Terminated Biodegradable Lipids For The Delivery Of Active Agents | LIPA, CETP, APOB | SMN1; SMN2 2502/4885MEN1 3507/4885MAPT 3622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.